Print this page
-
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.
Protocol: 072201Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer.
Protocol: 072509Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Other Digestive Organ -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (pf-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072510Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Pancreas -
A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE).
Protocol: 072204Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Esophagus
Stomach -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Understanding the Role of Pepsinogen and Gut Microbiome as a Biomarker of Cancer in the Gastrointestinal Tract.
Protocol: 072208Principal Investigator:
- Haejin In
Applicable Disease Sites: Stomach -
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis STOPGAP II
Protocol: 072603Principal Investigator:
- Haejin In
Applicable Disease Sites: Esophagus
Stomach -
Pilot of Streamlined Follow-up Pathway for Patients with Potential Gastrointestinal Cancer Identified in the Emergency Department: Baseline Metrics, Acceptance and Feasibility
Protocol: 072302Applicable Disease Sites: Colon
-
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers.
Protocol: 072401Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Other Digestive Organ -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas -
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer.
Protocol: 072407Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Anus -
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma.
Protocol: 072502Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Liver